Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Wilmington, NC
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Dublin, OH
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Dublin, OH
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Warwick, RI
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Columbia, SC
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Fort Worth, TX
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Vienna, VA
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Vienna, VA
Click here to add this to my saved trials
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated:  9/29/2017
Novo Nordisk Investigational Site
mi
from
Burlington,
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Status: Enrolling
Updated: 9/29/2017
Novo Nordisk Investigational Site
mi
from
Burlington,
Click here to add this to my saved trials
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Vasodilator Therapy and Exercise Tolerance in IPF Patients
Status: Enrolling
Updated:  9/29/2017
VA Medical Center, Miami
mi
from
Miami, FL
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Vasodilator Therapy and Exercise Tolerance in IPF Patients
Status: Enrolling
Updated: 9/29/2017
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
University of Alabama
mi
from
Birmingham, AL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Community Medical Research
mi
from
Miami, FL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Community Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Community Medical Research - North Miami
mi
from
North Miami, FL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Community Medical Research - North Miami
mi
from
North Miami, FL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Massachusetts General
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Massachusetts General
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
St. Vincent Hospital
mi
from
Worcester, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
St. Vincent Hospital
mi
from
Worcester, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Clinical Research Associates
mi
from
Nashville, TN
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Clinical Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Vanderbilt University School of Medicine
mi
from
Nashville, TN
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Benchmark Research
mi
from
San Angelo, TX
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Benchmark Research
mi
from
San Angelo, TX
Click here to add this to my saved trials
Brain Glutamate Receptors and Cocaine Dependence
Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving
Status: Enrolling
Updated:  10/5/2017
National Institute on Drug Abuse, Biomedical Research Center
mi
from
Baltimore, MD
Brain Glutamate Receptors and Cocaine Dependence
Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving
Status: Enrolling
Updated: 10/5/2017
National Institute on Drug Abuse, Biomedical Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Andalusia, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Andalusia, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Foley, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Foley, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Jasper, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Jasper, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Mobile, AL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Chandler, AZ
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Flagstaff, AZ
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Peoria, AZ
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Fresno, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Fullerton, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Gold River, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Gold River, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Newport Beach, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Orange, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Rancho Mirage, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
San Jose, CA
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Aurora, CO
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Colorado Springs, CO
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Clearwater, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Coral Gables, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Hialeah, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Kissimmee, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Miami, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Ormond Beach, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Panama City, FL
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Panama City, FL
Click here to add this to my saved trials